Home » Newsletters » BioWorld Science

BioWorld Science

May 28, 2007

View Archived Issues

Clinical studies of new drugs to treat disorders of reduced GI motility

Novel immunosuppressants disclosed by Sankyo

Recent Tsumura patents impart novel therapeutic agents for diabetic retinopathy

New treatments for musculoskeletal and connective tissue disorders claimed in recent patents

Efficacy and safety of linaclotide acetate in women with constipation-predominant IBS

PSN-GK1: a glucokinase activator with glucose-lowering and insulinotropic activity in vivo

Clinical research reported at the 2007 Society of Biological Psychiatry meeting

New ceramide derivatives beneficial in models of chronic skin inflammatory disease

Dexloxiglumide shows utility for c-IBS in phase III trial

Phase I study under way for ABT-107

Oral calcitonin begins phase III for treatment of osteoarthritis

Nycomed and Micromet to develop anti-GM-CSF antibodies

Marketing agreement signed for PSD-502 for premature ejaculation

U.S. orphan drug designation for Vekacia in vernal keratoconjunctivitis

VaxGen discontinues development of recombinant anthrax vaccine

New site added in phase II trial of atiprimod in advanced carcinoid cancer

Exjade labeling receives new Warning and Adverse Reactions information

New phase II/III trial investigates CDX-110 in glioblastoma multiforme

Exelixis files IND for XL-019

Preterax evaluation closes in ADVANCE diabetes trial

Sanofi-aventis recaps quarterly highlights

CHMP hands down negative opinion for Vectibix in metastatic colorectal cancer

Increlex recommended for approval in E.U.

Novel xanthine oxidase inhibitors for gout emerge from Kissei R&D

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...